Technique
No molecule left behind
We’re devoted to empowering focused and flexible genomic coverage, enabling ultra-high sensitivity and reducing costs.
Our technology is optimized to ensure low-frequency mutant molecule (<0.05%) detection with high specificity.
Our products are customizable for our BioPharma partners to focus on novel clinical biomarker hypotheses.

Technology
Liquid biopsy assays designed for BioPharma clinical development
Detect genetic alterations at very low mutant allele frequencies with purpose-designed, ultra-sensitive tests.
Ensure the most efficient approach to patient enrollment in clinical trials for targeted therapies through reliable identification of even the lowest frequency mutations.
Expert-designed Plasma-Safe-SeqS panels are cost-effective, ultra-sensitive NGS liquid biopsy solutions that aid in identifying tumor mutations across cancer types.
With Plasma-Safe-SeqS, 100% of the starting molecules are analyzed, which isn’t always the case with other methods or technologies. This chart shows that with Plasma-Safe-SeqS, the input molecules are not lost along the sequencing process like they commonly can be with other methods or technologies. The chart shows the sample input of benign molecules and mutant molecules remain intact throughout sample amplification, multiplexing, dilution, purification, and quantification. The second part of the chart shows that 40% of molecules could be lost during sample preparation prior to ligation/hybrid-capture based next-generation sequencing (or NGS), which could lead to a false negative or inaccurate analysis.
General help line:
For more information on the data in the table, contact us at info@sysmexinostics.com
Biopharma Offerings
From pioneer to gold standard in liquid biopsy
This chart shows our Biopharma Offerings with a timeline starting in 2008 showing the progression to the current year of 2021. We offer lab services and single-site PMA in addition to the distributed kit. Our lab services include patient testing, clinical assay development, in vitro diagnostics (IVD), and CDx. We offer CLIA testing services to inform a physician of treatment options for patients, investigational testing for clinical assay development, testing for registration trials, and post-market patient testing. Applications are for patients and oncologists, co-development for pharma, testing for academic investigators, pharma in late Tx development, and clinical laboratories.